A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers.
Leanne HamertonKelly GomesRonan FougerayEmma S KnowlesMarta Vargas GomesOle HauchAsh BullementPublished in: Future oncology (London, England) (2023)
Background: The current work was designed to estimate the cost-effectiveness of trifluridine/tipiracil (T/T) versus best supportive care (BSC) for patients with advanced stage or metastatic gastroesophageal cancer (mGC) from a UK perspective. Materials & methods: A partitioned survival analysis was undertaken using data from the phase III TAGS trial. A jointly fitted lognormal model was selected for overall survival and individual generalized gamma models were chosen for progression-free survival and time-to-treatment-discontinuation. The primary outcome was the cost per quality-adjusted life year (QALY) gained. Sensitivity analyses were undertaken to investigate uncertainty. Results: Compared with BSC, T/T was associated with a cost per QALY gained of £37,907. Conclusion: T/T provides a cost-effective treatment option for mGC in the UK setting.
Keyphrases
- free survival
- phase iii
- metastatic colorectal cancer
- squamous cell carcinoma
- small cell lung cancer
- clinical trial
- open label
- healthcare
- cross sectional
- palliative care
- phase ii
- deep learning
- machine learning
- randomized controlled trial
- double blind
- combination therapy
- childhood cancer
- pain management
- electronic health record
- chronic pain
- big data
- replacement therapy
- smoking cessation